| 17alpha-ethynylestradiol | multiple interactions | ISO | RGD:1312253 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of OXCT1 mRNA | CTD | PMID:17942748 |
| 17alpha-ethynylestradiol | affects expression | ISO | RGD:1312253 | 6480464 | Ethinyl Estradiol affects the expression of OXCT1 mRNA | CTD | PMID:17555576 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:1312253 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of OXCT1 mRNA | CTD | PMID:17942748 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1312253 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of OXCT1 mRNA | CTD | PMID:19770486 PMID:21496263 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1312252 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of OXCT1 mRNA | CTD | PMID:21496263 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1312253 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of OXCT1 mRNA | CTD | PMID:19770486 |
| 5-fluorouracil | multiple interactions | ISO | RGD:1312252 | 6480464 | TP53 protein affects the reaction [Fluorouracil results in decreased expression of OXCT1 mRNA] | CTD | PMID:15016801 |
| 5-fluorouracil | affects response to substance | ISO | RGD:1312252 | 6480464 | OXCT1 protein affects the susceptibility to Fluorouracil | CTD | PMID:16217747 |
| 7H-xanthine | multiple interactions | EXP | | 6480464 | [Xanthine co-treated with XDH protein] results in decreased expression of OXCT1 protein | CTD | PMID:19464573 |
| 9H-xanthine | multiple interactions | EXP | | 6480464 | [Xanthine co-treated with XDH protein] results in decreased expression of OXCT1 protein | CTD | PMID:19464573 |
| aflatoxin B1 | decreases expression | ISO | RGD:1312253 | 6480464 | Aflatoxin B1 results in decreased expression of OXCT1 mRNA | CTD | PMID:19770486 |
| amiodarone | increases expression | EXP | | 6480464 | Amiodarone results in increased expression of OXCT1 mRNA | CTD | PMID:17991464 |
| benzo[a]pyrene | decreases expression | ISO | RGD:1312252 | 6480464 | Benzo(a)pyrene results in decreased expression of OXCT1 mRNA | CTD | PMID:20064835 |
| benzo[a]pyrene | decreases expression | ISO | RGD:1312253 | 6480464 | Benzo(a)pyrene results in decreased expression of OXCT1 mRNA | CTD | PMID:19770486 |
| bromobenzene | decreases expression | EXP | | 6480464 | bromobenzene results in decreased expression of OXCT1 mRNA | CTD | PMID:15056800 |
| chlorpyrifos | decreases expression | EXP | | 6480464 | Chlorpyrifos results in decreased expression of OXCT1 mRNA | CTD | PMID:20691718 |
| choline | multiple interactions | ISO | RGD:1312253 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of OXCT1 mRNA | CTD | PMID:20938992 |
| ciguatoxin CTX1B | affects expression | ISO | RGD:1312253 | 6480464 | Ciguatoxins affects the expression of OXCT1 mRNA | CTD | PMID:18353800 |
| cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of OXCT1 mRNA | CTD | PMID:22023808 |
| cobalt dichloride | decreases expression | ISO | RGD:1312252 | 6480464 | cobaltous chloride results in decreased expression of OXCT1 mRNA | CTD | PMID:19320972 |
| coumestrol | increases expression | ISO | RGD:1312252 | 6480464 | Coumestrol results in increased expression of OXCT1 mRNA | CTD | PMID:19167446 |
| coumestrol | multiple interactions | ISO | RGD:1312252 | 6480464 | [Coumestrol co-treated with resveratrol] results in increased expression of OXCT1 mRNA; more ... | CTD | PMID:19167446 |
| cyclosporin A | decreases expression | ISO | RGD:1312253 | 6480464 | Cyclosporine results in decreased expression of OXCT1 mRNA | CTD | PMID:19770486 |
| dibutyl phthalate | increases expression | EXP | | 6480464 | Dibutyl Phthalate results in increased expression of OXCT1 mRNA | CTD | PMID:21266533 |
| dibutyl phthalate | increases expression | ISO | RGD:1312253 | 6480464 | Dibutyl Phthalate results in increased expression of OXCT1 mRNA | CTD | PMID:21266533 |
| folic acid | multiple interactions | ISO | RGD:1312253 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of OXCT1 mRNA | CTD | PMID:20938992 |
| fonofos | increases methylation | ISO | RGD:1312252 | 6480464 | Fonofos results in increased methylation of OXCT1 promoter | CTD | PMID:22847954 |
| L-methionine | multiple interactions | ISO | RGD:1312253 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of OXCT1 mRNA | CTD | PMID:20938992 |
| mitoxantrone | affects response to substance | ISO | RGD:1312252 | 6480464 | OXCT1 protein affects the susceptibility to Mitoxantrone | CTD | PMID:16217747 |
| mono(2-ethylhexyl) phthalate | affects expression | ISO | RGD:1312253 | 6480464 | mono-(2-ethylhexyl)phthalate affects the expression of OXCT1 mRNA | CTD | PMID:21195148 |
| morphine | decreases expression | EXP | | 6480464 | Morphine results in decreased expression of OXCT1 protein | CTD | PMID:23056601 |
| nickel sulfate | decreases expression | ISO | RGD:1312252 | 6480464 | nickel sulfate results in decreased expression of OXCT1 mRNA | CTD | PMID:16780908 |
| parathion | increases methylation | ISO | RGD:1312252 | 6480464 | Parathion results in increased methylation of OXCT1 promoter | CTD | PMID:22847954 |
| pirinixic acid | multiple interactions | ISO | RGD:1312253 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of OXCT1 mRNA | CTD | PMID:19710929 |
| pirinixic acid | decreases expression | ISO | RGD:1312253 | 6480464 | pirinixic acid results in decreased expression of OXCT1 mRNA | CTD | PMID:18445702 PMID:17426115 |
| pirinixic acid | decreases expression | ISO | RGD:1312253 | 6480464 | pirinixic acid results in decreased expression of OXCT1 mRNA | CTD | PMID:17426115 PMID:18445702 |
| resveratrol | multiple interactions | ISO | RGD:1312252 | 6480464 | [Coumestrol co-treated with resveratrol] results in increased expression of OXCT1 mRNA | CTD | PMID:19167446 |
| tamoxifen | multiple interactions | EXP | | 6480464 | [Tamoxifen results in increased activity of NOA1 protein] which results in decreased activity of OXCT1 protein | CTD | PMID:17283165 |
| terbufos | increases methylation | ISO | RGD:1312252 | 6480464 | terbufos results in increased methylation of OXCT1 promoter | CTD | PMID:22847954 |
| testosterone | decreases expression | ISO | RGD:1312253 | 6480464 | Testosterone results in decreased expression of OXCT1 mRNA | CTD | PMID:20403060 |
| thiabendazole | affects expression | EXP | | 6480464 | Thiabendazole affects the expression of OXCT1 mRNA | CTD | PMID:18539377 |
| trans-resveratrol | multiple interactions | ISO | RGD:1312252 | 6480464 | [Coumestrol co-treated with resveratrol] results in increased expression of OXCT1 mRNA | CTD | PMID:19167446 |
| trichloroethene | affects expression | ISO | RGD:1312253 | 6480464 | Trichloroethylene affects the expression of OXCT1 mRNA | CTD | PMID:21135412 |
| vancomycin | increases expression | ISO | RGD:1312253 | 6480464 | Vancomycin results in increased expression of OXCT1 mRNA | CTD | PMID:18930951 |